Apollo Therapeutics, a biopharmaceutical company focused on translating fundamental medical research into medicines through a hub-and-spoke approach, has closed $226.5 million in a Series C financing, led by lead investor Patient Square Capital.
Financing significantly adds to the $195 million previously raised by the company, and to Apollo’s pipeline of over 20 programmes with multiple near and medium-term value catalysts and uncorrelated risk.
Proceeds will be used to advance pipeline programmes through clinical development and further fund Apollo’s drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, as well as to licence or acquire additional clinical stage programmes that meet strict selection criteria.
Current partner institutions are: The University of Cambridge, Imperial College London, University College London, King’s College London, and The Institute of Cancer Research.
Dr Richard Mason, Chief Executive Officer of Apollo Therapeutics, said: “Apollo has built a broad and diversified pipeline focused on major commercial markets and this latest fund-raising enables us to take our most advanced programs to key clinical value inflection points.”
